Innogene Q1 2026: Revenue Up but Net Loss

Q1 2026 revenue: 2.59 billion won (46.6% increase YoY from 1.77 billion)
Operating loss: 176 million won (loss widened from 27 million in Q1 2025)
Net loss: 96 million won (swung from net profit of 45 million in Q1 2025)
New care food (agricultural products) revenue: 699 million won (tax-exempt, business diversification)
Lawsuit provision of 30.3 million won paid; appeal ongoing
Cash and equivalents: 1.18 billion won, no debt
Dividend paid: 985 million won (reduced equity)
R&D expenses: 59.3 million won (down from 73.0 million in Q1 2025)
Reversal of inventory valuation loss: 18.9 million won

ADVERTISEMENT (250px+)